01—Abstract
Summary
Summary of the 10-Q filed March 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported total net revenue of $1.681 billiona for the third fiscal quarter ended January 31, 2025, a slight increase of 1% compared to the prior year period.
This growth was driven by the Life Sciences and Diagnostics Markets segment, which saw a 4% increase, and the Agilent CrossLab segment, which grew by 1%. However, the Applied Markets segment experienced a 4% decline in revenue. Net income for the quarter was $318 millionb, down from $348 million in the same quarter last year, with diluted earnings per share of $1.11 compared to $1.18 in the prior year.
Despite a slight revenue increase, the company saw a decrease in overall profitability and a decline in gross and operating margins. The company also repurchased $90 millionc of its common stock during the quarter and maintained its quarterly dividend, reflecting a continued commitment to returning capital to shareholders.
Agilent's cash position remains strong, with cash and cash equivalents totaling $1.467 billiond. The company has reorganized its reporting segments, and management anticipates a steady recovery in customer capital budgets while remaining optimistic about long-term market health.
02—Key points
Key Highlights
- Total net revenue increased by 1% year-over-year to $1.681 billion.
- Life Sciences and Diagnostics Markets segment revenue grew by 4%, while Agilent CrossLab grew by 1%.
- Applied Markets segment revenue declined by 4% year-over-year.
- Net income decreased to $318 million from $348 million in the prior year period.
- Diluted earnings per share were $1.11, down from $1.18 in the prior year.
- The company repurchased $90 million of its common stock during the quarter.
- Cash and cash equivalents remained strong at $1.467 billion.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Agilent Technologies, Inc. kept $0.19.
- Revenue$1.68B100.0%
- Cost of revenue−$782.0M46.5%
- Gross profit$899.0M53.5%
- Operating costs−$523.0M31.1%
- Operating income$376.0M22.4%
- Interest, other & tax−$58.0M3.5%
- Net income$318.0M18.9%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed March 3, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $1.68B$1.66B | +1.4% |
| Cost of Revenue | $782.00M$750.00M | +4.3% |
| Gross Profit | $899.00M$908.00M | −1.0% |
| R&D Expenses | $113.00M$128.00M | −11.7% |
| SG&A Expenses | $410.00M$396.00M | +3.5% |
| Operating Expenses | $1.30B$1.27B | +2.4% |
| Operating Income | $376.00M$384.00M | −2.1% |
| Interest Expense | $28.00M$22.00M | +27.3% |
| Net Income | $318.00M$348.00M | −8.6% |
| EPS (Basic) | $1.12$1.19 | −5.9% |
| EPS (Diluted) | $1.11$1.18 | −5.9% |
| Shares Outstanding (Basic) | 285.00M293.00M | −2.7% |
| Shares Outstanding (Diluted) | 287.00M294.00M | −2.4% |
05—Questions
Frequently Asked Questions
What was Agilent's revenue performance in the third fiscal quarter?
Agilent Technologies reported total net revenue of $1.681 billion for the third fiscal quarter ended January 31, 2025, representing a 1% increase compared to the same period last year. Revenue from the Life Sciences and Diagnostics Markets and Agilent CrossLab segments increased, while the Applied Markets segment experienced a decrease.
How did Agilent's profitability change compared to the previous year?
Net income for the quarter was $318 million, a decrease from $348 million in the prior year's comparable quarter. Diluted earnings per share also decreased to $1.11 from $1.18 year-over-year, indicating a reduction in profitability.
What actions did Agilent take regarding capital allocation during the quarter?
During the three months ended January 31, 2025, Agilent repurchased $90 million of its common stock under its 2023 repurchase program. The company also continued its dividend payments, declaring a quarterly dividend of $0.248 per share.
How has Agilent reorganized its business segments?
In November 2024, Agilent announced a restructuring that combines its former Diagnostics and Genomics segment with liquid chromatography and mass spectrometry platforms into a new Life Sciences and Diagnostics Markets segment. The chemistries, supplies, laboratory automation, and software divisions moved to the Agilent CrossLab segment, and the remaining divisions form the new Applied Markets segment. This new structure is reflected in the financial reporting starting this quarter.
06—Continue